Semaglutide is a long-acting synthetic analogue of glucagon-like peptide-1 (GLP-1), a 31-amino-acid incretin hormone. It binds to the GLP-1 receptor and is the subject of an extensive published research literature on glucose homeostasis and energy balance.

Is semaglutide a controlled substance in the UK?

Semaglutide is not a controlled substance under the Misuse of Drugs Act. As a licensed medicine in the UK (Wegovy, Ozempic, Rybelsus), human therapeutic use is regulated by the MHRA and requires a prescription. Research reference material supplied for laboratory use is outside this prescription pathway and is not intended or approved for human consumption.

What endpoints have semaglutide clinical trials reported?

The published STEP and SUSTAIN programmes report on glycated haemoglobin (HbA1c), body weight, fasting plasma glucose, and cardiovascular endpoints in defined patient populations. These results describe the licensed medicine in clinical trial settings and are not predictive of any outcome from research reference material.

Semaglutide: UK Regulatory Status and Published Research Summary

Semaglutide is a long-acting GLP-1 receptor agonist that has been the subject of one of the largest peptide clinical trial programmes published to date. This article summarises the UK regulatory position and the published research literature in a research-only framing. It does not describe how to obtain, prescribe, dose or use semaglutide in people, and nothing in this article should be read as medical or pharmacy advice.

UK Regulatory Status

In the UK, semaglutide is a prescription-only medicine (POM) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA) under three licensed brands manufactured by Novo Nordisk: Ozempic (subcutaneous, type 2 diabetes), Wegovy (subcutaneous and, since June 2026, oral tablets, weight management) and Rybelsus (oral, type 2 diabetes). Each brand has a separate MHRA marketing authorisation, Summary of Product Characteristics (SmPC), and indication. Access to these licensed medicines is solely a matter for a registered prescriber and a licensed pharmacy, and falls outside the scope of this site.

Research-grade semaglutide reference material, of the kind referenced in laboratory and preclinical literature, is supplied as an unlicensed research chemical. It is not licensed or approved by the MHRA for human use, and is not interchangeable with the licensed brands above.

Mechanism of Action (Published Research)

Semaglutide is a 31-amino-acid analogue of human GLP-1 with substitutions and a C18 fatty acid side chain (Lau et al., 2015) that extend its plasma half-life to approximately one week, according to the US prescribing information. In published mechanistic and clinical studies it has been characterised as a selective agonist at the GLP-1 receptor, with reported effects on:

Glucose-dependent insulin secretion from pancreatic beta cells (in vitro and clinical pharmacology data, for example Kapitza et al., 2017)
Suppression of glucagon release under hyperglycaemic conditions (Kapitza et al., 2017)
Delayed first-hour gastric emptying measured by paracetamol absorption, with overall emptying over five hours not significantly different from placebo (Hjerpsted et al., 2018)
Central nervous system signalling at brainstem and hypothalamic GLP-1 receptors associated with food intake regulation in animal models (Gabery et al., 2020)

Reported Clinical Trial Endpoints

The published STEP (weight management) and SUSTAIN (type 2 diabetes) trial programmes have reported on, among other endpoints:

Change in HbA1c from baseline in adults with type 2 diabetes
Change in body weight from baseline in defined adult populations (for example STEP 1 and STEP 2)
Composite cardiovascular outcomes in SUSTAIN-6 (Marso et al., NEJM, 2016)
Adverse event profile, dominated by gastrointestinal events during titration

These endpoints describe the licensed medicine administered under trial protocols and supervision. They are not predictive of any outcome from research reference material and are reported here purely as published literature.

Oral Semaglutide (Research Interest)

The licensed oral formulation (Rybelsus and an oral Wegovy formulation, launched in the US in January 2026 and approved by the MHRA in June 2026) is co-formulated with the absorption enhancer sodium N-[8-(2-hydroxybenzoyl)amino] caprylate (SNAC), which aids absorption of semaglutide in the stomach (Buckley et al., 2018). It is one of the few oral peptide products to reach approval (Drucker, 2020). Researchers interested in oral peptide delivery often reference these formulations in absorption-enhancer literature, separately from any prescribing context. See our analysis of the oral GLP-1 research landscape.

Adverse Events Reported in Published Trials

Gastrointestinal events (nausea, vomiting, diarrhoea, constipation) dominate the reported safety profile in the STEP and SUSTAIN programmes, with reported incidence figures broadly aligned with other GLP-1 receptor agonists. Less common serious events reported include pancreatitis and gallbladder (biliary) disease, and the US prescribing information carries a boxed warning relating to rodent thyroid C-cell tumour findings. Lean body mass changes during body-weight reduction have been reported in published trials; a 2026 meta-analysis of randomised trials attributed about 35% of the weight lost with semaglutide to lean mass (Eisa et al., 2026).

Comparative Research Context

Semaglutide is frequently referenced alongside the dual GIP/GLP-1 agonist tirzepatide and the triple GIP/GLP-1/glucagon agonist retatrutide in incretin pharmacology literature. Researchers comparing these molecules typically refer to differences in receptor selectivity, half-life and reported trial endpoints rather than head-to-head therapeutic positioning. See our tirzepatide vs semaglutide research summary and retatrutide vs tirzepatide notes.

References

Buckley ST, et al. (2018). Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine. PubMed 30429357
Davies M, et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. PubMed 33667417
Drucker DJ. (2020). Advances in oral peptide therapeutics. Nature Reviews Drug Discovery. PubMed 31848464
Eisa N, et al. (2026). Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Diabetes, Obesity and Metabolism. PubMed 41877354
Gabery S, et al. (2020). Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. PubMed 32213703
Hjerpsted JB, et al. (2018). Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes, Obesity and Metabolism. PubMed 28941314
Kapitza C, et al. (2017). Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial. Diabetologia. PubMed 28526920
Lau J, et al. (2015). Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. PubMed 26308095
Marso SP, et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. PubMed 27633186
Wilding JPH, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. PubMed 33567185